Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation - The New England Journal of Medicine - 2019
Brief Summary:
Among patients with AF presenting with ACS or undergoing PCI, apixaban is associated with a 4.2% absolute reduction in major or clinically relevant nonmajor bleeding when compared to warfarin at 180 days. Apixaban was also associated with a 3.9% absolute reduction in death or hospitalization when compared to warfarin (driven primarily by reduced hospitalization). Aspirin use in addition to oral anticoagulation and P2Y12 inhibitor therapy was associated with a 7.1% absolute increase in major or clinically relevant nonmajor bleeding. Overall thrombotic events were similar across individuals randomized to anticoagulation with apixaban versus warfarin, and those randomized to aspirin versus placebo.Reference: http://www.ncbi.nlm.nih.gov/pubmed/30883055
Amazing, What an Excellent post. I truly discovered this an excessive amount of data. It is the thing that I was looking for.I might want to recommend you that please continue sharing such kind of information. buy apixaban
ReplyDelete